Larry Mathis Financial Planning LLC Purchases Shares of 5,770 Astrazeneca Plc $AZN

Larry Mathis Financial Planning LLC acquired a new position in Astrazeneca Plc (NYSE:AZN) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 5,770 shares of the company’s stock, valued at approximately $1,013,000. Astrazeneca accounts for approximately 0.9% of Larry Mathis Financial Planning LLC’s investment portfolio, making the stock its 29th largest position.

Several other large investors have also made changes to their positions in the business. IHT Wealth Management LLC boosted its stake in Astrazeneca by 0.3% during the 4th quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock valued at $3,076,000 after purchasing an additional 54 shares during the period. Visionary Wealth Advisors lifted its holdings in shares of Astrazeneca by 1.5% during the fourth quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock worth $737,000 after buying an additional 60 shares during the last quarter. Vista Investment Management lifted its holdings in shares of Astrazeneca by 0.3% during the fourth quarter. Vista Investment Management now owns 21,215 shares of the company’s stock worth $3,723,000 after buying an additional 60 shares during the last quarter. Kestra Investment Management LLC boosted its position in shares of Astrazeneca by 1.9% in the fourth quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock valued at $595,000 after acquiring an additional 63 shares during the period. Finally, Luken Investment Analytics LLC boosted its position in shares of Astrazeneca by 4.3% in the fourth quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock valued at $274,000 after acquiring an additional 64 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Stock Down 0.0%

Shares of AZN stock opened at $174.87 on Friday. The stock has a market cap of $271.20 billion, a P/E ratio of 26.26, a price-to-earnings-growth ratio of 1.52 and a beta of 0.25. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71. The stock has a fifty day moving average price of $186.62 and a 200 day moving average price of $186.27. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The firm had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Analysts predict that Astrazeneca Plc will post 9.39 earnings per share for the current year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.